

Financial news for CERU dated on 2017-07-19: Companies Holding Shareholder Meetings Today Include: Cerulean Pharma, Nivalis Therapeutics, Reynolds American, Supervalu, TFS Financial, and Wipro Ltd.

Financial news for CERU dated on 2017-07-05: Dare Bioscience Distributes Letter to Cerulean Stockholders Outlining Value Proposition, Requesting Favorable Vote at Upcoming Special Stockholder Meeting

Financial news for CERU dated on 2017-06-27: Cerulean Pharma Issues Release Urging Holders To Vote 'FOR' All Proposals At Upcoming Shareholder Meeting On Jul. 19

Financial news for CERU dated on 2017-06-19: Cerulean Pharma Sends Letter From Pres, CEO To Holders Urging Vote 'FOR' All Co. Director Nominees

Financial news for CERU dated on 2017-04-17: 8-K from Cerulean Pharma Shows Expectation for Cash, Cash Equivalents as of Jun. 30, 2017 to be \$4M-\$6M

Financial news for CERU dated on 2017-03-28: Dare Bioscience Reports 20.7% Stake In Cerulean Pharma

Financial news for CERU dated on 2017-03-20: Cerulean Shares Resume, Now Down ~64%

Financial news for CERU dated on 2017-03-20: Cerulean Pharma And Dare Science To Operate Under Dare Bioscience Name, Appoints Sabrina Martucci Johnson CEO

Financial news for CERU dated on 2017-03-20: UPDATE: Cerulean To Sell Dynamic Tumor Targeting Platform To Novartis For \$6M

Financial news for CERU dated on 2017-03-20: UPDATE: Cerulean Reduces Workforce By 11 People, Sells CRLX101 and CRLX301 To BlueLink Pharmaceuticals For \$1.5M

Financial news for CERU dated on 2017-03-20: Cerulean Pharma and Dare Bioscience Enter into Stock Purchase Agreement Where Equityholders of Dare Bioscience Will Become Majority Owners Of Cerulean

Financial news for CERU dated on 2017-03-20: Cerulean Shares Halted News Pending

Financial news for CERU dated on 2017-03-15: Cerulean Shares Up 9.3% Premarket

Financial news for CERU dated on 2017-03-14: Cerulean Shares Down ~9% Premarket

Financial news for CERU dated on 2017-03-13: Several Biotherapeutics Stocks Outperforming: Cerulean Pharma Up 44%, Adaptimmune 16%, Aurinia 15%, Versatem 14.5%, Heat Biologics 14%, Calithera 14%

Financial news for CERU dated on 2017-02-01: Cerulean Shares to Resume Trade at 8:30 a.m. EST

Financial news for CERU dated on 2017-02-01: Cerulean Announces Review of Strategic Alternatives To Maximize Shareholder Value, Engages Aquilo Partners As Financial Advisor

Financial news for CERU dated on 2017-02-01: Cerulean Pharma Halted News Pending

Financial news for CERU dated on 2016-08-18: Wedbush Downgrades Cerulean Pharma to Neutral, Lowers PT to \$1.00

Financial news for CERU dated on 2016-08-18: Leerink Swann Downgrades Cerulean Pharma to Market Perform

Financial news for CERU dated on 2016-08-18: Janney Capital Downgrades Cerulean Pharma to Neutral

Financial news for CERU dated on 2016-08-18: JMP Securities Downgrades Cerulean Pharma to Market Perform

Financial news for CERU dated on 2016-02-24: Barclays Maintains Overweight on Cerulean Pharma, Lowers PT to \$5.00

Financial news for CERU dated on 2016-02-02: Roth Capital Reinstates Buy on Cerulean Pharma

Financial news for CERU dated on 2016-01-06: Janney Capital Initiates Coverage on Cerulean Pharma at Buy

Financial news for CERU dated on 2015-09-22: Barclays Initiates Coverage on Cerulean Pharma at Overweight, Announces \$8.00 PT

Financial news for CERU dated on 2015-08-28: Roth Capital Initiates Coverage on

Cerulean Pharma at Buy, Announces \$9.00 PT

Financial news for CERU dated on 2015-06-01: Cerulean Presents Full Data from Phase 1b/2 Trial of CRLX101 in Combination with Avastin in Metastatic RCC ta ASCO

Financial news for CERU dated on 2015-05-26: Cerulean's CRLX101 Receives Orphan Drug Designation from FDA for Treatment of Ovarian Cancer

Financial news for CERU dated on 2015-04-07: Cerulean Pharma Prices 5.84M Share Offering @\$6.00/Share

Financial news for CERU dated on 2015-03-19: Cerulean Announces Phase 1b/2 Trial of CRLX101 in Combination with Avastin(r) in Relapsed Renal Cell Carcinoma Meets Primary Endpoint

Financial news for CERU dated on 2015-03-03: Cerulean Establishes Clinical Collaboration with the GOG Foundation to Study CRLX101 in Combination with Weekly Paclitaxel in Relapsed Ovarian Cancer

Financial news for CERU dated on 2014-05-06: Leerink Swann Initiates Coverage on Cerulean at Outperform, Announces \$13.00 PT

Financial news for CERU dated on 2014-05-06: Wedbush Initiates Coverage on Cerulean at Outperform, Announces \$12.00 PT

Financial news for CERU dated on 2014-05-06: Canaccord Genuity Initiates Coverage on Cerulean at Buy, Announces \$11.00 PT

Financial news for CERU dated on 2014-05-06: JMP Securities Initiates Coverage on Cerulean at Market Outperform, Announces \$14.00 PT